Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 10 January 2017 | By Michael Mezher
The US Food and Drug Administration (FDA) on Tuesday issued one draft guidance recommending a label advisory for over-the-counter (OTC) products containing aspirin, and finalized another recommending a warning label for OTC acetaminophen-containing products.
For many years the medical community has debated over the benefits and risks of taking low-dose daily aspirin to lower the risk of cardiovascular disease.
Last year, the US Preventive Services Task Force recommended taking low-dose daily aspirin for patients between 50 and 69 years old that at are risk for cardiovascular disease, but only after speaking with their doctor. However, other studies have shown that taking daily aspirin can lead to other health problems, including gastrointestinal bleeding and ulcers.
According to FDA, most OTC aspirin products are marketed under the tentative final monograph (TFM) for internal analgesic, antipyretic, and antirheumatic (IAAA) drug products for the temporary relief of a variety of minor aches and pains, including headache, backache, toothache, premenstrual cramps.
FDA's own regulations, however, allow for OTC aspirin-containing products to be labeled for cardiovascular events, but only in the sections of the label directed at healthcare professionals (e.g. clinical pharmacology, pharmacokinetics and animal toxicology).
In its new draft guidance, FDA says drugmakers should add an advisory instructing patients to consult with their doctor before taking aspirin for cardiovascular conditions if the product contains heart-related imagery, such as a stethoscope around a heart.
FDA also finalized a guidance, first introduced in 2014, instructing drugmakers to include a warning statement informing patients that acetaminophen may cause severe, and potentially fatal, skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
In 2013, FDA issued a drug safety communication warning of rare but serious skin reactions caused by acetaminophen-containing products after conducting a review of cases from the agency's FDA Adverse Event Reporting System (FAERS) database.
For both products, FDA says it does not intend to take enforcement action against manufacturers that include the recommended statement or warning, as long as they are otherwise in compliance with the TFM for IAAA drugs and other applicable regulations.
Federal Register – Aspirin
Federal Register – Acetaminophen
Tags: Aspirin, Acetaminophen
Regulatory Focus newsletters
All the biggest regulatory news and happenings.